Sign in
Taking peoplePhase 1

The REValve Clinical Trial an Evaluation Of the ReValve Palmetto Valve for the Replacement of the Native Mitral VaLVE

Key facts

Who runs it
ReValve Solutions Inc.
Where
Georgia3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 1
People taking part
20 people, planned
Started
1 Sept 2026
Expected to end
1 Dec 2028
Type of study
Interventional
Treatments tested
  • ReValve System
Record updated
29 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (13)Hide the full registry criteria

Who can take part

  • Symptomatic MR (≥3+) due to ischemic and non-ischemic cardiomyopathy etiology determined by assessment of a qualifying transthoracic echocardiogram (TTE) obtained within 60 days and transesophageal echocardiogram (TEE) obtained within 90 days prior to subject registration, with MR severity based principally on the TTE study
  • New York Heart Association (NYHA) Functional Class II, III or ambulatory IV
  • Left Ventricular Ejection Fraction (LVEF) is ≥30% (within 90 days prior to subject registration, assessed by the site using any one of the following methods: echocardiography, contrast left ventriculography, gated blood pool scan or cardiac magnetic resonance imaging (MRI))
  • Age greater than 18 years
  • Left Ventricular End Systolic Dimension (LVESD) is ≤ 65 mm assessed by site based on a transthoracic echocardiographic (TTE) obtained within 90 days prior to subject consent

Who cannot take part

  • Status 1 heart transplant or prior orthotopic heart transplantation
  • Cerebrovascular accident within 30 days prior to subject's consent
  • Currently participating in an investigational drug or another device study
  • Untreated clinically significant coronary artery disease requiring revascularization
  • Need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months
  • Known hypersensitivity or contraindication to procedural, post procedural medication (e.g., contrast solution, anticoagulation therapy) or hypersensitivity to nickel or titanium
  • Pregnant or planning pregnancy within next 12 months
  • Evidence of LV or left atrium (LA) thrombus, vegetation or mass

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Mitral regurgitation

This trial is currently available in Georgia.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

An evaluation of the ReValve System for treatment of clinically significant mitral regurgitation in subjects determined appropriate for mitral valve surgery.

The group in the trial

  • Single Arm StudyTreatment being tested

    Treatment: ReValve System

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Clinical Study Evaluating the Replacement of the Native Mitral Valve Using the ReValve System
Criteria questions
Built from NCT07450911, who can take part
Record updated
29 September 2026